Cell therapy specialist ReNeuron Group PLC (LON:RENE) said new data will be presented that demonstrate the feasibility of scaling up production of ReNeuron's CTX-derived exosomes.
Exosomes are nanoparticles released by cells that are believed to play a key role in cell-to-cell communication.
READ: First person treated in ReNeuron’s mid-stage US stroke trial
A growing body of evidence suggests they can modulate cellular immunity and/or promote the activation of regenerative or repair programmes in diseased or injured cells.
Dr Nicola Goddard, of University College London, will tell a California conference the exomes scale-up was achieved using state-of-the-art bioreactor systems.
The ability to generate exomes in this way, ReNeuron said, represented a “significant advance towards an industrial-scale production process without affecting the quality and consistency of the final product”.
The company is working with Goddard and the team as part of a cell and gene therapy collaboration part-funded by a government grant.
Goddard will take to the podium at the ECI conference in Coronado later today (Jan 31). For more information click here.